Joaquin Lopez-Martinez
Madrid, MD, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Measurable residual disease (MRD) dynamics in multiple myeloma and the influence of clonal diversity analyzed by artificial intelligence.
Journal: Blood cancer journal
Published: March 22, 2024
Correction: Large-scale real-life analysis of survival and usage of therapies in multiple myeloma.
Journal: Journal of hematology & oncology
Published: July 25, 2023
Large-scale real-life analysis of survival and usage of therapies in multiple myeloma.
Journal: Journal of hematology & oncology
Published: March 12, 2023
A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma.
A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma.
Journal: Blood cancer journal
Published: January 11, 2022
Impact of COVID-19 in patients with multiple myeloma based on a global data network.
Journal: Blood cancer journal
Published: October 27, 2021
Making clinical decisions based on measurable residual disease improves the outcome in multiple myeloma.
Journal: Journal of hematology & oncology
Published: June 29, 2021
NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma.
Journal: Blood cancer journal
Published: August 05, 2020
Natural killer cells efficiently target multiple myeloma clonogenic tumor cells.
Journal: Cancer immunology, immunotherapy : CII
Published: February 18, 2020
Myeloproliferative neoplasm in a thalassaemic patient: response to treatment with a JAK inhibitor.
Journal: Annals of hematology
Published: January 24, 2015
Showing 1-9 of 9
Last Updated: 09/26/2026